Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia
JAMA
.
2021 Mar 2;325(9):830-832.
doi: 10.1001/jama.2021.1395.
Authors
Neerav Shukla
1
,
Maria Luisa Sulis
1
Affiliation
1
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
PMID:
33651075
DOI:
10.1001/jama.2021.1395
No abstract available
Publication types
Editorial
Comment
MeSH terms
Adolescent
Antibodies, Bispecific
B-Lymphocytes
Child
Disease-Free Survival
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Recurrence
Young Adult
Substances
Antibodies, Bispecific
blinatumomab